Sugi Predict

Sugi Predict / Targets / GGPS1

GGPS1

Geranylgeranyl pyrophosphate synthase · O95749 · GGPS1 on Sugi Atlas →

40,703 patent compounds predicted against GGPS1, 17,123 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Ibandronic Acid Ibandronic Acid (SCHEMBL9183) 1.00 8/20
SCHEMBL53288 SCHEMBL53288 0.53 8/20
SCHEMBL51672 SCHEMBL51672 0.51 8/20
SCHEMBL51889 SCHEMBL51889 0.51 8/20
SCHEMBL52096 SCHEMBL52096 0.51 8/20
SCHEMBL52100 SCHEMBL52100 0.51 8/20
SCHEMBL52131 SCHEMBL52131 0.51 8/20
SCHEMBL52156 SCHEMBL52156 0.51 8/20
SCHEMBL52180 SCHEMBL52180 0.51 8/20
SCHEMBL52220 SCHEMBL52220 0.51 8/20
SCHEMBL52239 SCHEMBL52239 0.51 8/20
SCHEMBL52268 SCHEMBL52268 0.51 8/20
SCHEMBL52340 SCHEMBL52340 0.51 8/20
SCHEMBL52347 SCHEMBL52347 0.51 8/20
SCHEMBL52351 SCHEMBL52351 0.51 8/20
SCHEMBL52352 SCHEMBL52352 0.51 8/20
SCHEMBL52354 SCHEMBL52354 0.51 8/20
SCHEMBL52360 SCHEMBL52360 0.51 8/20
SCHEMBL52387 SCHEMBL52387 0.51 8/20
SCHEMBL52402 SCHEMBL52402 0.51 8/20

Clinical trials — most relevant to GGPS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia PHASE3COMPLETED
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia PHASE3COMPLETED
Predicting the Response to Montelukast by Genetic Variation in Asthmatics PHASE3COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC PHASE2COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate PHASE2WITHDRAWN
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults PHASE2UNKNOWN
Simvastatin in Secondary Progressive Multiple Sclerosis PHASE2COMPLETED
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study PHASE2UNKNOWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis EARLY_PHASE1COMPLETED
GSNOR Phenotyping/GSNO Challenge in Severe Asthma EARLY_PHASE1COMPLETED
RCDP Natural History Study nanUNKNOWN
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Statin Therapy Versus Placebo Prior to Prostatectomy nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A nanACTIVE_NOT_RECRUITING
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency nanRECRUITING
Clinical and Laboratory Analysis of Familial Cancer nanCOMPLETED
Genetic Epidemiology of Sarcoidosis nanCOMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Natural History of GACI With or Without ARHR2 or PXE nanUNKNOWN
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GGPS1 binder may also engage these)

ProteinNameSimilarity
P56966 — 1.000 P56966 →
Q6F596 — 1.000 Q6F596 →
Q9WTN0 — 1.000 Q9WTN0 →
A0A7D0AGU9 — 0.992 A0A7D0AGU9 →
Q43315 — 0.987 Q43315 →
Q7XYS9 — 0.984 Q7XYS9 →
Q4JHN6 — 0.983 Q4JHN6 →
P05369 — 0.983 P05369 →
P49351 — 0.983 P49351 →
P49352 — 0.981 P49352 →
A0A1V0QSH7 — 0.978 A0A1V0QSH7 →
Q920E5 — 0.978 Q920E5 →
P49350 — 0.978 P49350 →
O24242 — 0.977 O24242 →
Q7XYT0 — 0.976 Q7XYT0 →
P49353 — 0.976 P49353 →
O24241 — 0.976 O24241 →
A0A7J6HWR9 — 0.975 A0A7J6HWR9 →
O64905 — 0.975 O64905 →
Q8WMY2 — 0.974 Q8WMY2 →
Q09152 — 0.972 Q09152 →
F9WZD2 — 0.969 F9WZD2 →
P08836 — 0.968 P08836 →
Q9P885 — 0.966 Q9P885 →
P9WEQ2 — 0.960 P9WEQ2 →
P9WEW8 — 0.959 P9WEW8 →
Q4WEB8 — 0.958 Q4WEB8 →
Q92250 — 0.956 Q92250 →
P9WEX9 — 0.955 P9WEX9 →
FDPS Farnesyl pyrophosphate synthase 0.954 landscape →